The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Epithelial-mesenchymal transition in glioblastoma progression
Open accessAbstract
Epithelial-mesenchymal transition (EMT) is a reversible biological process that occurs in epithelial cells. EMT ultimately leads to the acquisition of a mesenchymal phenotype, characterized by increased cell motility and resistance to genotoxic agents. These processes mostly overlap with the acquirement of stem cell properties in differentiated tumor cells. With regard to gliomas, the clinical picture is heterogeneous, even within the same grades and histological categories of the disease. Furthermore, the areas of invasion and responses to radiochemotherapy are markedly different among cases, and occasionally even in the same patient. Such phenotypic diversity in glioma tissues may be caused by various microenvironmental factors, as well as intrinsic genetic alterations. The current review focuses on the EMT-inducing factors that are present in gliomas; these typically vary from those observed in epithelial cancers, as no basement membrane is present. Furthermore, the most important cell-cell contact factor, E-cadherin, is rarely expressed in gliomas. The microenvironment that induces EMT in gliomas is characterized by hypoxia and the enrichment of myeloid cells following stimulation by transforming growth factor-β. Anti-vascular endothelial growth factor therapy, including the use of bevacizumab, may be a suitable candidate to modulate the glioma microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“…important factors facilitating angiogenesis and resultant tumor growth in GBM. Inhibiting the VEGF-VEGF receptor (VEGFR) signal transduction pathway with anti-VEGF therapy (including the use of bevacizumab) and VEGFR inhibitors (including sunitinib) is a promising strategy in cancer therapy (80).”
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Biomarkers for epithelial-mesenchymal transitions
Zeisberg, M., & Neilson, E. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36183 · Cited by 2,299 · cited 12×
“Slug is another member of the SNAIL family of transcriptional activators and serves an important role in suppressing the epithelial phenotype in numerous cancer cells (1,2,44).”
BackgroundInfluential
Cited by
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
Glioblastoma hijacks neuronal mechanisms for brain invasion
Venkataramani, V., Yang, Y., Schubert, M. C., Reyhan, E., Tetzlaff, S. K., Wißmann, N., Botz, M., Soyka, S. J., Beretta, C. A., Pramatarov, R. L., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.054 · Cited by 632
Brain malignancies: Glioblastoma and brain metastases
Lah, T. T., Novak, M., & Breznik, B. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.010 · Cited by 438
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
3D‐Bioprinted Mini‐Brain: A Glioblastoma Model to Study Cellular Interactions and Therapeutics
Heinrich, M. A., Bansal, R., Lammers, T., Zhang, Y. S., Michel Schiffelers, R., & Prakash, J. (2019) · Advanced Materials · doi:10.1002/adma.201806590 · Cited by 317
Metadata
- Authors
- IWADATE, Y.
- Venue
- Oncology Letters
- Publisher
- Spandidos Publications
- Published
- 2016-01-14
- Volume
- 11
- Issue
- 3
- Pages
- 1615-1620
- ISSN
- 1792-1074 (ISSN-L)
- 1792-1082
- OpenAlex
- W2236918265
- Cited by
- 288
- References
- 82
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epithelial-mesenchymal transition in glioblastoma progression. https://app.cochat.ai/papers/10.3892/ol.2016.4113
- The paper
- IWADATE, Y. (2016). Epithelial-mesenchymal transition in glioblastoma progression. Oncology Letters. https://doi.org/10.3892/ol.2016.4113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.